title: Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.
abstract: Numerous studies have shown that Alzheimer's Disease (AD) pathology begins before the onset of clinical symptoms. Because therapies are likely to be more effective if they are implemented early in the disease progression, it is necessary to identify reliable biomarkers to detect AD pathology in the early stages of the disease, ideally in presymptomatic individuals. Recent research has identified three candidate cerebrospinal fluid (CSF) biomarkers that reflect AD pathology: amyloid beta, total tau protein (t-tau), and tau protein phosphorylated at AD-specific epitopes (p-tau). They are useful in supporting the AD diagnosis and have predictive value for AD when patients are in the stage of mild cognitive impairment (MCI). However, their predictive utility in cognitively healthy subjects is still being evaluated. We conducted a review of studies published between 1993 and 2011 and summarized their findings on the role of CSF biomarkers for AD in healthy elderly.
authors.affiliation: Center for Brain Health, New York, NY 10016, USA.
authors.forename: Catherine
authors.initials: C
authors.lastname: Randall
authors.forename: Lisa
authors.initials: L
authors.lastname: Mosconi
authors.forename: Mony
authors.initials: M
authors.lastname: de Leon
authors.forename: Lidia
authors.initials: L
authors.lastname: Glodzik
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000175:diagnosis; D001057:Apolipoproteins E / Q000134:cerebrospinal fluid; D015415:Biomarkers / Q000134:cerebrospinal fluid*; D006801:Humans; D012307:Risk Factors
chemical_list: D001057:Apolipoproteins E; D015415:Biomarkers